The symptoms that define mood, anxiety, and trauma disorders are highly overlapping across disorders and heterogeneous within disorders. It is unknown whether coherent subtypes exist that span multiple diagnoses and are expressed functionally (in underlying cognition and brain function) and clinically (in daily function). The identification of cohesive subtypes would help disentangle the symptom overlap in our current diagnoses and serve as a tool for tailoring treatment choices.
D
iagnostic criteria defined by the DSM-IV are heterogeneous within each disorder and overlap substantially between disorders, 1 as demonstrated by at least 50% of individuals having concurrent diagnoses from more than 1 category of anxiety and mood disorder at a given time. [2] [3] [4] [5] Heterogeneity within each disorder manifests not only at the symptom level but also in underlying behavior and physiology, and this limits the opportunity for health care professionals to understand disease mechanisms and to identify valid biomarkers for disease progression and intervention targets. Identifying such biomarkers is an urgent task, given that depression and anxiety have become the leading cause of disability and lost productivity worldwide 6 and that only onethird of people recover from treatment. 7 In this study, we propose a complementary data-driven approach to uncovering symptom clusters that are coherent across behavioral, physiological, and daily function levels.
In previous data-driven approaches in psychiatry, the focus has typically been on stratification based on symptom type or severity and behavior within a single diagnostic category (eg, schizophrenia, [8] [9] [10] psychotic disorders, 11, 12 depression, [13] [14] [15] [16] [17] attention-deficit/hyperactivity disorder, [18] [19] [20] and autism [21] [22] [23] ). This focus is important for data-driven discovery of subtypes within diagnostic categories but cannot address the need to characterize the heterogeneity and overlap of symptoms across diagnostic categories. Of the available data-driven studies of symptoms across multiple diagnoses, the focus has been on youth transdiagnostic samples. [24] [25] [26] To our knowledge, no study has documented valid symptom clusters in a cohort of adults spanning multiple mood, anxiety, and trauma disorders and integrated symptom cluster data with data from multiple levels of function.
To address these issues, our data-driven approach has 4 corresponding aims. Our first aim was to use unsupervised machine learning to identify naturally occurring transdiagnostic subgroups within representative samples spanning multiple mood, anxiety, and trauma diagnoses, including major depressive disorder (MDD), panic disorder, generalized anxiety disorder, obsessive-compulsive disorder, posttraumatic stress disorder (PTSD), and bipolar disorder type 2. Because of the large overlap in symptoms across these disorders, 27-30 they were considered appropriate for our approach. In this context, the term subgroup refers to transdiagnostic rather than within-diagnostic classification. Second, we sought to assess the robustness and generalizability of the resulting subgroups in an independent validation sample. Third, we integrated multiple sources of data to assess how subgroups differ with respect to independent and external metrics for neurocognitive performance and brain activation. We selected domains that encompass behavior, brain physiology, and self-reported functioning 31, 32 and that assess broad aspects of neurocognitive and behavioral dysfunction implicated multiple mood, anxiety, and stress disorders. 33 Fourth, we evaluated how daily functional capacity varied between the subtypes. Daily functioning was selected as an indicator of clinical meaning because it is considered a primary domain affected in individuals experiencing depression and anxiety symptoms. 34 To provide a complementary, theoretically driven diagnostic frame of reference for interpretation, we mapped our data-driven subtypes onto the original categories found in the DSM-IV. We hypothesized that participants would be represented in transdiagnostic, reproducible symptom clusters that map onto specific profiles of neurocognition, brain activation, and daily functional capacity. We further hypothesized that subtypes would cut across diagnostic boundaries.
Methods

Participants Primary Sample
Participants were recruited systematically by advertisements placed in outpatient and community health settings in the communities surrounding the University of Sydney, Australia, and the University of Adelaide, Australia. These samples are diverse with respect to race/ethnicity, age, and sex, and are therefore representative of the surrounding communities. Our protocol received independent institutional ethical review board approval of the Human Research Ethical Committees of the Sydney Medical School at the Western Sydney Area Health Service and the University of Sydney prior to recruitment of participants. All participants signed and dated an approved informed consent form. Data are from participants who consented to have their data made available to the Brain Research and Integrative Neuroscience Network Foundation Database, 35 for open sharing and secondary analysis by the research community. We recruited clinical participants who had 1 of 3 primary diagnoses (based on DSM-IV criteria): MDD, PTSD, and panic disorder. Diagnosis was made using the Mini-International Neuropsychiatric Interview 36 and Hamilton Depression Rating Scale 37 for MDD, the Clinician-Administered PTSD Scale 38 and the Struc-Comorbid mood and anxiety disorders were present. Of participants with a primary diagnosis of MDD (n = 100), comorbid conditions included PTSD (n = 12; 12%), panic disorder (n = 14; 14%), generalized anxiety disorder (n = 36; 36%), and attention-deficit/hyperactivity disorder (n = 1; 1%). Of participants with PTSD (n = 47), comorbid conditions included MDD (n = 17; 36%) and generalized anxiety disorder (n = 4; 9%). Of participants with panic disorder (n = 53), comorbid conditions included MDD (n = 7; 13%), PTSD (n = 15; 28%), generalized anxiety disorder (n = 5; 9%), dysthymia (n = 3; 6%), obsessive-compulsive disorder (n = 13; 25%), and seasonal affective disorder (n = 31; 59%) (additional data appear in eTable 1 in the Supplement).
Participants were excluded for lifetime and current medical conditions that could affect testing procedures. Exclusion criteria also included lifetime diagnoses of a neurological disorder, brain injury, or any other disorder affecting cognitive, sensory, and/or motor function or the presence of an ongoing substance use disorder (as defined by the DSM-IV).
A total of 497 adults with a mood, anxiety, or trauma disorder (n = 248) or healthy control status (n = 249) were enrolled. Healthy participants, recruited from equivalent communities in each population center, were matched for age and sex to clinical participants on a casewise basis. Those with incomplete symptom data (n = 77) were excluded from reporting, reducing the sample size to 420 participants with a mean (SD) age of 39.8 (14.1) years (range, 18-83 years); 256 (61.0%) were women.
Consistent with our focus on transdiagnostic heterogeneity, individuals were treated as 1 large transdiagnostic sample for the purpose of analysis. Details of recruitment and screening have been published previously 35, 41 and are documented further in the eMethods in the Supplement.
Independent Validation Sample
Data for the independent validation sample were acquired from a sample of 381 adult participants, of whom 207 (54.3%) were female. The mean (SD) age was 36.7 (14.6) years (range, 18 to 86 years). They were also recruited from community sources and tested at an academic center. 32 This transdiagnostic scope of this sample also encompassed MDD, PTSD, panic disorder, multiple comorbid disorders, and healthy control participants. (For comorbidity rates and details of inclusion and exclusion criteria, see the eMethods and eTable 2 in the Supplement.)
Self-Reported Symptoms
Negative mood was assessed by the Depression, Anxiety and Stress Scale, version 21 (DASS-21). 42 The DASS-21 is a selfreport scale for assessing 3 symptom areas common to mood, anxiety, and stress disorders, including subscales for depression (including low positive affect, low self-esteem, and sense of hopelessness), anxiety (encompassing fear, somatic features, and hyperarousal features) and stress (tension and irritability) (eTable 3 in the Supplement contains details on study measures We used well-established facial emotion paradigms for eliciting brain activation responses during the viewing of facial expressions under both conscious (unmasked) and nonconscious (masked) conditions. Facial emotion stimuli depicted expressions of fear, anger, sadness, and happiness, relative to a neutral expression. 57 The stimuli included 8 different individuals selected from a standardized series. 58 In each paradigm, the stimuli were grouped by the 8 individuals displaying the same emotion, with each grouping repeated 5 times.
In the nonconscious condition, facial emotion stimuli were presented below the threshold for conscious sensory detection. A Neuroscan Compumedics Nuamps system and an Quikcap Electrode System (Compumedics Ltd) were used to record EEG data according to the 10 to 20 electrode international system with 32 channels, including 4 electrooculography channels, an orbicularis oculus channel, and a masseter channel. The details of this well-established protocol have been published previously. 41 Informed by prior EEG research on negative mood states, we quantified data for primary frequency bands of focus-α (8-13 Hz) and β (14.5-30 Hz)-and these values were averaged for the frontal region (Fp1, Fp2, F7, F3, Fz, F4, and F8), the central region (FC3, FCz, FC4, C3, Cz, C4, CP3, CPz, and CP4), the temporal regions (T3, T4, T5, and T6), and the parietal/ occipital regions (P3, Pz, P4, O1, Oz and O2) bilaterally. 41, 53, 59 We designated θ (4-7.5 Hz) and δ (1.5-3.5 Hz) frequencies as secondary bands of interest, and we clarified in exploratory analyses that there were no significant effects for these bands. Outliers beyond 3 SDs from the mean of power values at each electrode site were mean-replaced. Drawing on prior findings for negative mood states, 60 we also quantified frontal α asymmetry according to a subtraction of the natural log transformation of α power for FC4 minus FC3. Cluster centers were plotted from 10 000 repeated subsamples to assess robustness of the clustering solution (eFigures 5-7 in the Supplement).
Daily Functional Capacity
Assessing the Reproducibility of the Clustering Solution in an Independent Validation Sample
To further evaluate robustness and reproducibility, we repeated our clustering methods in the independent validation sample. We performed a principal component analysis using item-level data from the DASS-21 and used the resulting component scores as inputs to the agglomerative hierarchical clustering created with the Ward error sum of squares algorithm, then evaluated how closely the resulting cluster centers matched the original cluster centers.
Expression of Putative Subtypes in Neurocognitive, Neurophysiological, and Daily Function Domains
We evaluated the extent to which subtypes differentiated on the external measures of neurocognition, neurophysiological, and daily functional status. One-way analysis of variance (ANOVA) tests were run to identify significant differences on each measure between the mean scores of the 6 subtypes. Variance explained by the 6-cluster solution was compared with that explained by DSM-IV diagnosis (eTable 4 in the Supplement); post hoc tests were also completed (eFigure 8 and eTable 5intheSupplement). Redundant variables within each measure were not analyzed to reduce comparisons and retain meaningful results. Multiple comparisons were addressed by using the Bonferroni correction (eMethods in the Supplement). Additional analysis of covariance tests that included comorbidity covariates were run, and variance explained by the 6-cluster solution was compared with variance explained by DSM-IV diagnosis (eTable 6 in the Supplement). For neurocognitive performance, ANOVA tests were run on each of the 9 tests, with a Bonferroni-corrected α level of P = .006. For neurophysiology measures, ANOVAs were run separately for electroencephalographic tests with eyes open and eyes closed and for conscious and nonconscious emotion conditions. In these ANOVAs, dependent variables were the 4 averaged regional power values for both α and β bands; thus, the corrected alpha level was P = .006. An ANOVA was run on the single measure of α asymmetry at P = .05. For self-reported daily function, ANOVAs were run on the 2 functioning domains of social skills and emotional resilience at the corrected alpha level of P = .03.
Results
Unsupervised Machine Learning Algorithms
Principal component analysis of the DASS-21 items revealed 3 components with the orthogonal rotation converging in 6 iterations (eTable 7 in the Supplement). Together, these components accounted for 71.2% of the total variance. Based on the loadings (eResults in the Supplement), the 3 components were named anhedonia, anxious arousal, and tension. The unsupervised machine learning algorithm identified a 6-cluster solution ( Figure 1 ). Each cluster, or subtype, had a 
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Each symptom component is a spatial dimension on the x-axis, y-axis, and z-axis.
distinct symptom profile (eFigure 9 in the Supplement). Based on each subtype's mean symptom component scores, they were interpreted as representing the following: normative mood (characterized by low symptom scores on all 3 components) (n = 180); tension (n = 81); anxious arousal (n = 55); general anxiety (n = 38); anhedonia (n = 29); and melancholia (n=37). Subtypes differed significantly in anhedonia, anxious arousal, and tension, as determined by 1-way analyses of variance ( 
Replication in Independent Sample
In an independent sample, principal component analysis identified the same 3-component solution of anhedonia, anxious arousal, and tension components (eResults and eTable 9 in the Supplement). Hierarchical clustering algorithms, using the 3 component scores as inputs, identified the same 6-cluster solution (eFigures 9 and 10 in the Supplement).
Expression in Behavioral Measures of Neurocognition
Subtypes were expressed in a differential profile of behavioral performance on tests of neurocognition ( Figure 2 ). Subtypes differed significantly in their cognitive control, as measured by the go/no-go test (z scores were −0.038 for people with normative mood, −0.012 for people with tension, −0.491 for people with anxious arousal, −0.903 for people with general anxiety, 0.057 for people with anhedonia, and −0.163 for people with melancholia; F 5,383 = 5.13; P < .001; η p 2 = 0.063). Subtypes also differed by working memory as measured by the digit span test (z scores were for 0.062 for people with normative mood, −0.116 for people with tension, −0.357 for people with anxious arousal, −0.209 for people with general anxiety, 0.158 for people with anhedonia, and −0.260 for people with melancholia; F 5,401 = 3.29; P = .01; η p 2 = 0.039). This difference was owing to particularly poor cognitive control and working memory for the anxious arousal subtype.
Expression in Neurophysiological Measures of Brain Activation
Subtypes were also expressed in a differential profile of resting brain activation, as assessed by the neurophysiological measure EEG power ( 
Comparison With Conventional Diagnostic Boundaries
Subtypes were mapped onto the original DSM-IV diagnostic categories to provide a complementary, theoretically driven frame of reference. Subtypes were shown to cut across diagnostic boundaries because frequency distributions showed subtypes were composed of participants from all diagnostic groups, revealing that cluster groups did not represent diagnosis. For instance, individuals with primary diagnoses of MDD and PTSD were distributed across all 6 subtypes ( Table 2 ; eResults, eTable 6, and eFigure 11 in the Supplement).
Discussion
This study demonstrates a novel approach to identifying subtypes defined by distinct profiles of symptoms that map onto unique patterns of neurocognition, brain activation, and clinically relevant daily functioning. A machine learning stratification algorithm, blind to diagnosis, identified 6 clusters of individuals based on specific symptom profiles. This 6-cluster solution was replicated in an independent sample, indicating the solution is reproducible. Each type demonstrated a unique profile across domains. Anxious arousal was distinguished by poor daily functioning and the greatest level of neurocognitive impairment compared with most subtypes, particularly in the cognitive control domain. General anxiety was characterized by an elevation in emotion-elicited parietooccipital β power as compared with the normative mood and anxious arousal subtypes, and intact daily functioning. Melancholia, in contrast, was distinguished by the poorest daily functioning, particularly social functioning, compared with the normative mood, tension, and general anxiety subtypes. Anhedonia was distinguished by specific elevations in resting frontal β power, and the tension subtype by average performance across domains despite severe symptoms of tension. Although previous studies have not examined multidomain profiles across multiple diagnoses, specific aspects of these profiles align with prior findings. Our observation of the poorest neurocognition in the anxious arousal subtype accords with previous within-diagnosis relationships between anxiety and impaired cognition. [63] [64] [65] [66] Our results align with the view that functional disability, spanning social and (especially) emotional domains, is a hallmark of melancholia.
67,68
The frontal β elevation observed for anhedonia is somewhat surprising, because β waves are often associated with active or anxious thinking. 69, 70 However, at least 1 previous study has shown a connection between increased β and depression specifically. 71 A possible account of the elevated parietal β and somewhat poor working memory of people with general anxiety is a parietally mediated compensation for core working memory dysfunction 72 ; however, in this study, the difference on working performance from other subtypes was not significant. By contrast, the relatively intact status of the tension subgroup may reflect more fundamental compensatory mechanisms or a state of stress that does not reach the level of disrupting daily life. Our approach demonstrates 1 application of a proposed model for ultimately developing a taxonomy for mental disorders that maps specific symptom profiles onto underlying neurobehavioral dimensions. There are important ways in which this approach should be further refined and expanded. Future studies should use additional data-driven techniques and independent samples to further test the robustness of subtype structures. Longitudinal designs (such as the Minnesota Twin Family Study 73 ) will help determine whether subtypes are stable over time, as has been shown within the diagnosis of major depression for adolescents and older adults. 13 To further elucidate the functional anatomical basis of the subtypes, high-density EEG data could be acquired for source localization. With in vivo imaging, we could anchor transdiagnostic subtypes in increasingly proximal measures of underlying brain circuits. 74, 75 Imaging should also be considered as primary inputs for clustering and validating solutions, alongside symptom measures. The Bipolar and Schizophrenia Network for Intermediate Phenotypes has advanced the identification of biotypes for psychosis based on cognitive and neurophysiological measures, 11 and validated with functional and imaging measures. 76 It will be important to incorporate information at many different domain levels and examine cross-level interactions 77 as a means to tap biological systems implicated in major psychiatric domains. Several foundational studies have used imaging of resting functional brain connectivity to identify neurophysiological biotypes within samples of depressed individuals. 78-80 These novel approaches have had a profound effect on our understanding of depression and reflect state-of-theart systems biology research needed to develop valid biotypes. The clinical utility of new subtype models ultimately rests on their value in helping guide intervention decisions. Because our data-driven approach yields groups of individuals that share symptom, behavioral, and brain activation profiles, it offers one way forward for considering new targets for intervention studies. For example, in light of the general anxiety subtype profiles, 1 such hypothesis would be that behavioral interventions targeting working memory would have a specific association with general anxiety symptoms and would be visible on associated working memory and emotion-elicited EEG β power end points.
Limitations
One limitation of our study is the relatively small number of individuals in each subtype and the overall small size of the sample. Over and beyond replication, larger samples are needed so that stratifications by sex, age, and symptom-defined subgroups retain large enough numbers in important strata. Data from a large number of participants, input into a data set for the machine learning processes used in this study, will allow additional latent constructs in the data to be uncovered.
Furthermore, this study used limited symptom data for subtype determination. These inputs were constrained by the need for common assessments across diagnoses and samples. Future research that expands the sample size and input features and uses complementary features for subtype determination will be essential in establishing a valid and clinically viable taxonomy for mood, anxiety, and trauma disorders.
Our analyses also focused on current Axis 1 diagnoses. Thus, we were unable to include data on the potential contributions of lifetime history of psychiatric disorder or history of substance use and other disorders. Future studies should include a lifetime history to ensure that all relevant domains underlying psychopathology are being tapped.
Conclusions
We demonstrate a data-driven approach for identifying transdiagnostic subtypes that are distinct, reproducible, and expressed across domains of symptoms, neurocognitive functioning, brain activation, and daily functioning. Because the symptom profiles map on to clinically relevant domains, they offer new targets for developing personalized treatments. Author Contributions: Ms Grisanzio and Dr Williams had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Grisanzio, 
Participants-Primary BRAINnet Sample
Participants who contributed data to this analyzed dataset were recruited from 5 medical research or clinical research sites. These sites agreed to collaborate to evaluate brain health in patients using a standardized set of assessments and contribute the data to a centralized library (the basis of the BRAINnet Foundation Database). The medical research sites were located in universities with teaching hospital outpatient clinics focused on the disorders of interest, and based in the same geographical communities as the controls (1). The recruitment of patients with MDD and PTSD was from the general community of the population center of Sydney, which is a diverse and representative area. The patients attended the Brain Dynamics Center for assessments (MDD) or the PTSD Unit for assessments (PTSD), both of which were physically based at Westmead Hospital, a teaching hospital for the Sydney Medical School. Thus, the patients were not recruited from academic center clinics but attended the academic center for their testing sessions. Panic Disorder participants were recruited from outpatient and community sources in the population center of Adelaide and tested at the Flinders University academic center, participating in the BRAINnet database. Healthy control subjects were recruited from the same geographical regions and socioeconomic backgrounds as the clinical subjects.
Inclusion criteria for all participants in regard to the capacity to undergo a computerized test were: reading at Year 5 level (equivalent to Year 6 in England and 5th grade in the United States), normal (or corrected to normal) vision, and ability to use a keyboard. Participants were additionally required to refrain from smoking and caffeinated beverages for at least 2 hours prior testing, and to refrain from alcohol for at least 12 hours prior to testing.
Exclusion criteria for healthy control participants included a personal or first degree family history of DSM-IV Axis I disorders, or a personal history of brain injury, neurological disorder or other serious medical condition, sleep or learning disorders, or drug or alcohol addiction (using the Alcohol Use Disorders Identification Test -AUDIT) of the World Health Organization (2) and the Fagerstrom Tobacco Dependency Questionnaire (3). Healthy controls were also screened for symptoms of mood, anxiety and trauma disorders using the Somatic and Psychological Health Report (SPHERE; (4)). The SPHERE is a 34-item scale that rates both the psychological and somatic symptoms of these disorders.
MDD participants were either medication naïve (70%) or washed out for at least five half-lives of the medication at the time of testing. Two PTSD patients were on SSRIs during the testing period, and 50% of PTSD patients had comorbid MDD. PTSD participants also had no history of brain injury, loss of consciousness, stroke, neurological disorder, or other serious medical conditions (e.g., CVD and diabetes). Patients were ruled out for current substance use disorder, psychosis, and personality disorders. Average time post trauma was 65 months (SD = 64 months). PTSD was related to trauma due to assault in 50% of patients and due to being in car accidents involving a fatality in the remaining 50%. Panic Disorder exclusion criteria included a personal history of neurological disorder, physical brain injury, or serious medical problems and substance use disorder (same as for the other groups). No patient had taken benzodiazepine medication within the 2 weeks prior to assessment. 32 patients had used no psychotropic medication for at least 6 months prior to testing. Of the remaining, 13 were taking SSRIs at the time of testing, and 7 were taking SNRI, tri-cyclic or MAO antidepressant medication. Based on patient diaries including self-reported DSM-IV defined symptoms over the two-week period following testing, Panic Disorder patients reported a mean Panic Disorder Severity Scale (PDSS) score of 12.12 and a total number of Panic Attacks (during this two week period) of 4.12.
Comorbidities were present in the sample (see eTable 1).
Participants-Independent Validation "RAD" Sample
Data for the independent validation sample was an expanded sample that incorporated participants from the Research domain criteria Anxiety and Depression ("RAD") project, an observational study focusing transdiagnostically on the spectrum of depression and anxiety psychopathology. Consistent with the goal of RDoC, screening, and exclusion criteria were kept to a minimum. Inclusion criteria included: i) age (18+ years) to focus on the adult brain, ii) fluent and literate in English in order to understand task instructions, and iii) currently reporting mood and anxiety symptoms. Exclusion criteria included: i) current or lifetime experience of frank psychosis and/or mania, because the circuit dysfunctions associated with such phenomenology might obscure interpretation of anxiety and mood-related circuit dysfunctions, ii) presence of suicidal intent representing imminent risk as indicated during screening and on-site assessments, iii) medical condition or neurological disorder that could impact brain imaging data and render images difficult to interpret, iv) history of physical brain injury or blow to the head resulting in loss of consciousness greater than five minutes and which in the judgment of investigators could interfere with interpretation of brain imaging assessments, and v) severe impediment to vision, hearing and/or hand movement, likely to interfere with the ability to complete the assessments, or follow the instructions.
90% of participants were free of antidepressant medications and other medications that could impact assessments. Participants were enrolled in the study from 2013 to 2017. Patients were enrolled from the Gronowski Center, a community mental health training clinic, and individuals from the immediate surrounding community. Comorbid mood and anxiety disorders were present (see eTable 2). Lifetime disorders were also assessed for Major Depressive Disorder (40.9%), Panic Disorder (21.5%), Bipolar II Disorder (4.7%). Bipolar I Disorder (7.3%), and Bipolar NOS (6.3%).
Behavioral Measure of Cognition: Integneuro
For data reduction, we first took into account those variations in measures attributable to age and sex. A ''peer regression modeling'' technique was used, based on well-established psychometric principles. Age was modeled using both linear and logarithmic terms, and sex was modeled using a linear term. The expected score for each measure on each task was subtracted from the participant's actual score, and the resulting difference was divided by the standard error of the estimate of the regression equation.
For details on cognitive measures, see eTable 3.
Neurophysiological Measure of Brain Activation: LabNeuro
Participants were assessed in a controlled environment, seated in a comfortable chair in a dimly lit room. Data were recorded continuously with a sampling rate of 500Hz, with a virtual ground and an average reference. Horizontal eye movements were recorded with electrodes 1.5cm lateral to the outer canthus of each eye and vertical eye movements, with electrodes placed 3mm above the middle of the left eyebrow and 1.5cm below the middle of the left bottom eye-lid. Skin resistance was < 5 KOhms. Data were EOG corrected offline based on the established Gratton algorithm (5). For quantification of power spectra, we employed Fast Fourier Transformation (FFT).
Facial Emotion Paradigms
Emotion images were modified such that the eyes were presented in the central position of the image. 50% of the faces were female. The threshold for subliminal presentations, defined by a lack of sensory awareness, was established in an initial signal detection study (6) .
For details on EEG measures, see eTable 3.
Self-Reported Functional Status: BRISC
Correlation analyses between the BRISC scales and the World Health Organization Quality of Life-BREF (WHOQOL-BREF; (7)), Satisfaction with Life Scale (SWLS; (8)), and Health Productivity Questionnaire (HPQ; (9)), at a corrected P-value of 0.01, demonstrated 1) positive correlations between higher emotional resilience and higher scores on the WHOQOL-BREF psychological component (r = 0.52, P < 0.001) and satisfaction with life on the SWLS (r = 0.34, P = 0.01), and 2) positive correlations between higher social skills and higher scores on the WHOQOL-BREF components of physical health (r = 0.45, P = 0.001) and environment (r = 0.56, P < 0.001), satisfaction with life (r = 0.42, P = 0.001) and presenteeism on the HPQ (r = 0.37, P = 0.008) (1).
For details on functioning measures, see eTable 3.
Data Analysis Bonferroni Corrected Alphas
Multiple comparisons were addressed by using the Bonferroni Correction. For neurocognitive performance, ANOVAs were run on each of the nine tests, with a Bonferroni corrected alpha level of p=0.006. For neurophysiology measures, ANOVAs were run separately for EEG eyes open and closed and for conscious and nonconscious emotion conditions. In these ANOVAs, dependent variables were the four averaged regional power values for both alpha and beta bands; thus, the corrected alpha level was p=0.006. An ANOVA was run on the single measure of alpha asymmetry at p=.05. For self-reported daily function, ANOVAs were run on the two functioning domains of social skills and emotional resilience at the corrected alpha level of p= 0.03. Notes: Measures used to evaluate the extent to which subtypes were expressed in the electrocortical measure of brain activation. EEG measures relevant to mood, anxiety and stress disorders: acute threat ("fear"), loss ("sad"), and resting state were quantified. Statistical analyses were conducted using the stats, psych, cluster and factoextra packages in R, and NumPy, SciPy, IPython, Jupyter, matplotlib and scikit-learn packages in Python.
The PCA was run with a varimax rotation to ensure the independence of components. The three-component PCA solution aligned with the three DASS-21 subscales (Depression, Anxiety, and Stress), with the exception of two items. The item, "I was aware of dryness in my mouth," falls under the DASS Anxiety subscale, but loaded more highly onto our third "tension" component, and the item "I felt that I was using a lot of nervous energy" is included in the DASS Stress subscale, but loaded more highly onto our second "anxious arousal" component. Because component scores are "weighted" based on the importance of each item in the component, and therefore provide more information than subscale totals alone, component scores rather than DASS subscales were used in subsequent analyses. PCA loadings can be found in eTable 4.
Optimal Cluster Number Determination
The optimal number of clusters was determined using 1) the gap statistic a metric that compares the change in within-cluster dispersion with that expected under a reference null distribution (a distribution with no obvious clustering) (10) (eFigure 1) 2) the Calinski-Harabasz method, which identifies the number of clusters based on the ratio of between-cluster variance to within-cluster variance (11) (eFigure 2), 3) the elbow method, a graphical method that shows the percentage of variance explained as a function of number of clusters (eFigure 3), and 4) the dendrogram, a tree diagram that shows relative similarity between cases (eFigure 4).
The gap statistic compares the difference between within-cluster dispersion with what is expected under a null distribution as a function of cluster number (10) . The optimal number of clusters indicated by this metric is the solution that yields the largest gap statistic, signifying the clustering solution is far from a null distribution (i.e. a uniform distribution of points). We calculated the gap statistic for 2 to 20 clusters. The number of Monte Carlo bootstrapping samples ("B" copies of the reference data sets) used was B=500. This metric was maximized at a sixcluster solution (eFigure 1).
The Calinski-Harabasz method identifies the number of clusters based on the ratio of inter-cluster variance to intra-cluster variance (11) . Larger scores denote more optimal clustering solutions since it indicates both a large separation between clusters and low separation within clusters. We calculated the Calinski-Harabasz index for 2 to 20 clusters and found the index was maximized at a six-cluster solution (eFigure 2).
The elbow method is a graphical method that shows the percentage of variance explained as a function of cluster number. Based on this method, the number of clusters should be chosen in such a way that adding an additional cluster doesn't significantly improve the modeling of the data (or percentage of variance explained). When plotted, this point can be identified by locating the "elbow" in the plot. We calculated the sum of squared errors (SSE) for 2-20 clusters and located an elbow at 6 clusters (eFigure 3). Because the elbow method is based on visual interpretation, we used this as a secondary method to confirm the gap statistic and Calinski-Harabasz values.
The dendrogram is a tree diagram that shows the relative similarity between cases, and are organized into branches that represent the clusters. Visual analysis of the diagram confirmed a six-cluster solution fits the data (eFigure 4). These four metrics combined strongly indicate a six-cluster solution is optimal in our dataset.
K-Means Clustering Method as Comparison Clustering Method
To ensure our clustering solution was not a specific result of our clustering method, we used scikit-learn's K-means algorithm as a validating clustering method. Specifically, we 1) ran the K-means algorithm seeded with centroids using the K-means++ method, and 2) performed K-means clustering using the resulting cluster centroids of the hierarchical cluster solution. When using the K-means++ algorithm, the cluster centers are initialized in a way that probabilistically favors larger distances between them. When repeated, this method will tend to result in the globally optimal solution, whereas the solution obtained from seeding K-means with the hierarchical centroids can only be treated as a local optimum. Using the solutions found by both methods, we were able to quantify the difference in performance between the global solution and our local solution. In both cases, the K-means algorithm was run ten times (maximum number of iterations for each run: 300), and the solution with the lowest inertia (sum of squared distances for each point to its closest centroid) was used. K=6 was selected as the number of clusters, as this was reliably determined to be the most optimal. In the resulting cluster solutions, individuals were largely assigned to the same cluster group for both K-means++ (Adjusted Rand Index: 0.79) and seeded K-means (Adjusted Rand Index: 0.80) when compared to the initial hierarchical clustering solution. Additionally, the similarity in performance indicates that the solution found using the hierarchical centroids was the global optimum.
Fit of Individuals to Cluster Assignment
To evaluate how well each individual fit their cluster assignment, we calculated the silhouette scores for individuals in our clustering solution. A silhouette analysis is a commonly used metric of cluster cohesion (how similar an object is to its own cluster) compared to separation (how far it is to neighboring clusters) (12) . The average silhouette score for our clustering solution was 0.34.
Stability of Clustering Solution
To evaluate the stability of the clustering solution, we repeated our clustering analysis in 10,000 randomly selected subsamples, each containing 70% of the subjects. In each subsample, we re-ran the same PCA and hierarchical clustering methods as in the original analysis. We chose a six-cluster solution for all subsamples given 1) six was strongly supported to be the optimal number of clusters in the full sample, and 2) in a sample reduced by 30% and original cluster sizes of as small as n=29, allowing cluster number to vary would potentially result in entire clusters being missed. We evaluated the stability of the resulting 10,000 cluster centers by plotting the resulting center locations (eFigure 5 and 6).
We also evaluated the stability of cluster assignments at the individual subject level. In each of the 10,000 subsamples, subjects left out of the cluster identification process (the remaining 30%), were assigned to clusters using linear discriminant analysis classifiers. This left out sample was combined with the left-in sample to form a complete cluster solution. We then tested whether the individual cluster assignments were stable over the 10,000 subsamples by calculating an adjusted Rand score to test the similarity between each clustering solution compared to the original clustering solution (eFigure 7). The average adjusted Rand score was 0.69 (min 0.34, max 0.92).
Subtypes are Replicated in Independent Validation Sample
The three components revealed from the PCA in the independent validation sample closely matched the component loadings in the primary BRAINnet sample (eTable 5). Pearson correlations were run to compare the loadings between components in the validation sample compared to the primary sample (Anhedonia: r = 0.966, p < 0.001; Anxious Arousal: r = 0.779, p < 0.001; Tension: r = 0.866, p < 0.001).
These three components were the inputs to the same hierarchical clustering algorithm used in the primary analysis; agglomerative hierarchical clustering with Ward error sum of squares algorithm was run using the R cluster package. A six-cluster solution was chosen for this validation for the specific aim of evaluating whether the six-cluster solution in the primary analysis replicated in an independent sample. This analysis yielded the same sixcluster solution: Normative Mood, Tension, Anxious Arousal, General Anxiety, Anhedonia, and Melancholia. The symptom profiles of each subtype were replicated in the validation sample (eFigures 8 and 9).
There was a strong equivalence in the structure of the cluster solution across the BRAINnet and the independent RAD validation sample. The profile of scores characterizing each cluster showed the same structure across samples (eFigure 8). This equivalence is especially striking given that the cluster algorithm was run entirely independently for the validation sample, and because the validation sample was acquired at a different time, location, and with a different participant population. Within the context of this overall reproducibility of the cluster structure, there were two small differences across samples in the severity of specific symptom component features that characterized specific clusters. First, for the Anhedonia subtype cluster, participants in the BRAINnet sample had slightly higher severity on the Anhedonia component and slightly lower severity on the Tension component than did participants in the RAD sample. This variation in severity did not impact the equivalence of the overall structure of this cluster, which followed the same U-shaped profile across samples (eFigure 8). Second, for the Melancholia subtype, participants in the BRAINnet sample had slightly lower severity on the Anxious Arousal component than did participants in the RAD sample. Again, however, this variation in severity occurred in the context of a reproducible profile structure for this subtype. It is possible that participant population differences account for these variations in severity within the context of consistent overall cluster structures.
Types Transcend Diagnostic Boundaries
An assumption of our clustering approach was that clusters would not represent diagnostic groups (i.e. Cluster 1 = MDD, Cluster 2 = Panic Disorder, Cluster 3 = PTSD). To test this assumption, we examined the percentage of individuals within each diagnosis that were assigned to each of the six clusters (eTable 6). Additionally, chi-squared tests revealed differences in the frequencies of individuals across cluster, that are important to assess (controls: Each diagnostic group had a unique pattern. Controls, while assigned predominantly to the normative mood cluster, had 25% of individuals assigned to the Tension cluster, with a couple individuals spread between the remaining four clusters. The MDD participants were almost equally split between Anxious Arousal, Anhedonia, and Melancholia cluster. The Panic Disorder participants, in contrast, were represented mainly in the Normative Mood, Anxious Arousal, and General Anxiety clusters. The PTSD participants also had a unique distribution, being more evenly split than the other diagnostic groups across all six clusters, with comparatively more representation in the Anxious Arousal and General Anxiety clusters. These results give strong evidence that the clustering solution does not represent diagnosis, and that diagnosis splits between the clusters in different patterns.
Consideration of Sex Differences
It is important to consider sex differences in the clusters, as sex differences may affect domain structure. A chi-square test revealed there was no statistically significant association between sex and cluster ( 2 =4.09, p =0.54). eTable 7 shows the sex distribution by cluster.
Comparison of Variance Explained by Cluster Versus Diagnosis
We examined the variance explained by both the 6-cluster solution and conventional DSM groups (eTable 8). Partial eta squared values we calculated as variance measures. The 6-cluster solution explained more variance than DSM diagnosis on the working memory, cognitive control, emotion EEG beta, resting EEG beta, social skills, and resilience measures.
Because the clustering solution explained more variance than diagnosis on each of these external measures, we are confident in claiming that our clustering approach can, at minimum, offer additional information about individuals at the symptom, neurocognitive, neurophysiological, and functioning domain levels, that can be used as a complementary approach alongside diagnostic groupings.
Consideration of Comorbidity: Comparison of Clustering Solution vs. Diagnosis
We further examined the variance explained by the 6-cluster solution compared to DSM groups by including comorbid disorders as covariates (eTable 9). Comorbid disorders of Panic Disorder, Generalized Anxiety Disorder, Post-traumatic Stress Disorder, Attention-Deficit/Hyperactivity Disorder, Major Depressive Disorder, Dysthymia, Obsessive-Compulsive Disorder, and Social Anxiety Disorder were included as covariates in an Analysis of Covariance (ANCOVA) test. The results for the cluster versus diagnosis comparison, without comorbidity, outlined above, held for this ANCOVA. That is, the 6-cluster solution explained more variance than diagnosis, with comorbid disorders as covariates, on working memory, cognitive control, resting EEG beta, emotion EEG beta, and social skills. The only exception was that diagnosis with these covariates explained more variance on the resilience measure of daily functioning. This result suggests that resilience may be a functional capacity that is to a large extend independent of transdiagnostic clusters defined by neurocognitive and brain-based measures.
Post-Hoc Tests using Tukey Honest Significant Difference (HSD)
To evaluate which individual groups differed from each other in our significant one-way ANOVA tests, we ran the Tukey HSD post-hoc test to compare the neurocognitive, EEG, and psychosocial function measures among subtype groups (eTable 10, eFigure 11).
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